株式会社カイノス

DOMS-IATRON Co., Ltd. (currently Kainos) was established with a capital stock of 30,000,000 yen as a developer of new products in the health care industry.

設立 : 1975年5月1日

Changed its name to Kainos Laboratories, Inc.

社名をKainos Laboratories, Inc.に変更。

Released the world’s first enzyme-based serum transaminase measurement reagent kit.

世界初の酵素を用いた血清アスパラギン酸トランスアミナーゼ測定キットを発売。

Formed a technical tie-up with Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin,Ltd.) on enzyme immunoassay method (EIA).

三井製薬（現バイエル薬品）と酵素免疫測定法（EIA）に関する技術提携を締結。

Entered into a technical tie-up agreement with Hitachi Chemical Co., Ltd.(Currently Hitachi Chemical Diagnostics Systems Co., Ltd.) on reagents for clinical analysis equipment.

日立化学（現日立化学ダイアグノスティクスシステムズ）と臨床分析用試薬に関する技術提携を締結。

Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA)

アメリカのGAMMA BIOLOGICALS社と血液輸血診断製品の販売契約を締結。

Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA).

Released an enzyme-based creatinine measurement reagent kit.

酵素を用いたクレアチニン測定試薬を発売。

Entered into a technical tie-up agreement with Nippon Kayaku Co., Ltd. on clinical examination reagents.

日本化薬と臨床検査試薬に関する技術提携を締結。

Entered into a technical tie-up agreement with Kirin Beer Co., Ltd. (Currently Kyowa Kirin Co., Ltd.) on clinical examination reagents.

キリンビール（現キッコーマン）と臨床検査試薬に関する技術提携を締結。

Moved production to Kasama Factory, and began production of biochemical and immunoserological reagents.

笠間工場に生産を移し、生化学・免疫血清学試薬の生産を開始。

Entered into a technical tie-up agreement with Asahi Chemical Industry Co., Ltd. (Currently Asahi Kasei Pharma Corporation) on clinical examination reagents.

アサヒ化学工業（現アサヒケーセイファーマ）と臨床検査試薬に関する技術提携を締結。

本社を東京都文京区本郷に移転しました。

本社を東京・本郷に移転。

Listed on JASDAQ.

JASDAQに上場。

Acquired ISO 9001 certification, an international standard for quality assurance.

ISO 9001認証を取得。

NASBA特許のライセンス契約をオルガノン・テクニカ株式会社と締結しました（NASBA Gene Amplification特許の所有権がオルガノン・テクニカ株式会社からバイオメルジュへ移転されました）。

Organon Teknika B.V.とNASBA特許のライセンス契約を締結（所有権はbioMerieuxに移転）。

Entered into a distributorship agreement for genetic products with bioMerieux Japan.

bioMerieux Japanと遺伝子関連商品の販売代理店契約を締結。

Launched marketing of an influenza detection reagent “Statmark™ Influenza A/B” that had been jointly developed by Nichirei Corporation (currently Nichirei Bioscience Inc,) and Kainos.

ニチレイと共同開発したインフルエンザ検出試薬「Statmark™ Influenza A/B」の販売を開始。

Created Kainos BB, Co. Ltd. by spinning out Kainos’ Blood Banking business (in June 2005) then changed the name of the spun out company to Immucor-Kainos, Inc. through a joint venture agreement established as a part of the ongoing collaborative effort between Immucor, Inc. and Kainos.

血液銀行事業を分離し、Kainos BB, Co. Ltd.を設立。後にImmucor-Kainos, Inc.に改名。

Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment.

ISO 13485認証を取得。

Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment.

ISO 13485認証を再取得。

Introduction of the Kainos Executive Office System. Established Compliance Center.

Kainosエグゼクティブオフィスシステムを導入。コンプライアンスセンターを設立。

Kainos-Immucor, Inc.’s (currently K. K. Immucor) stocks were transferred to Immucor, Inc.

Kainos-Immucor, Inc.の株式がImmucor, Inc.に譲渡される。

Entered into a distributorship agreement for blood transfusion diagnostics products with Grifols SA.

Grifols SAと血液輸血診断製品の販売代理店契約を締結。

Insurance coverage granted to the assays respectively measuring two fractions of blood carnitine using blood carmitine measuring reagents based on the enzyme cycling method.

血中カルニチンの2つの分画を酵素サイクル法で測定する試薬の保険適用を取得。

Insurance coverage granted to the diagnostic drug based on an ADAMTS13 activity measurement reagent for the thrombotic thrombocytopenic purpura.

ADAMTS13活性測定試薬を用いた診断薬の保険適用を取得。

アサヒケーセイファーマと株式譲渡契約を締結し、相互の事業関係を強化。

Concluded a share transfer agreement with Asahi Kasei Pharma Corporation to further enhance the mutual business relationship.

Capital tie-up with Gene Therapy Research Institution Co.,Ltd. by accepting a part of its third-party allotment of shares.

Gene Therapy Research Institutionと資本提携を実施。第三者割当増資を受け入れる。

Concluded a capital and business tie-up with Sysmex Corporation to further enhance the mutual business relationship.

Sysmex Corporationと資本・業務提携を締結。

Delisted from the Tokyo Stock Exchange Standard Market. Became a wholly owned subsidiary of Denka Co., Ltd.